Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer ...

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

Chemotherapy-induced myelosuppression (CIM) remains one of the most significant and underappreciated barriers to delivering ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

SCLC diagnosis involves imaging, biopsies, and lab tests to assess tumor spread and guide treatment decisions. Treatment options vary by stage, with surgery, chemotherapy, radiation, and immunotherapy ...

Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two drugs for the treatment of adults ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research presented at the American Society of Clinical Oncology (ASCO) 2025 conference is ...